Cerebrolysin therapy in Rett syndrome: clinical and EEG mapping study

Gorbachevskaya, N. L.; Bashina, V M; Gratchev, Vitali V; Изнак, А. Ф.

doi:10.1016/s0387-7604(01)00349-7

Cited by 26 publications

(26 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Their downside is the obvious potential for excessive synaptic modulation and for disrupting regions with preserved function. In 2001, there was one published open-label trial of cerebrolysin, a neuropeptide preparation that includes nerve growth factors [94]. Recently, there have been several trials of full-length recombinant IGF-1 and an active tripeptide component of IGF-1 (trofinetide) that may have a greater effect on glial processes [104].…”

Section: Drugs Tested In Rtt Trialsmentioning

confidence: 99%

Neurobiologically-based treatments in Rett syndrome: opportunities and challenges

Kaufmann

Stallworth

Everman

et al. 2016

Expert Opinion on Orphan Drugs

View full text Add to dashboard Cite

Introduction: Rett syndrome (RTT) is an X-linked neurodevelopmental disorder that primarily affects females, typically resulting in a period of developmental regression in early childhood followed by stabilization and severe chronic cognitive, behavioral, and physical disability. No known treatment exists beyond symptomatic management, and while insights into the genetic cause, pathophysiology, neurobiology, and natural history of RTT have been gained, many challenges remain. Areas covered: Based on a comprehensive survey of the primary literature on RTT, this article describes and comments upon the general and unique features of the disorder, genetic and neurobiological bases of drug development, and the history of clinical trials in RTT, with an emphasis on drug trial design, outcome measures, and implementation. Expert opinion: Neurobiologically based drug trials are the ultimate goal in RTT, and due to the complexity and global nature of the disorder, drugs targeting both general mechanisms (e.g., growth factors) and specific systems (e.g., glutamate modulators) could be effective. Trial design should optimize data on safety and efficacy, but selection of outcome measures with adequate measurement properties, as well as innovative strategies, such as those enhancing synaptic plasticity and use of biomarkers, are essential for progress in RTT and other neurodevelopmental disorders.

show abstract

Section: Drugs Tested In Rtt Trialsmentioning

confidence: 99%

Neurobiologically-based treatments in Rett syndrome: opportunities and challenges

Kaufmann

Stallworth

Everman

et al. 2016

Expert Opinion on Orphan Drugs

View full text Add to dashboard Cite

show abstract

“…Other researchers report that cerebrolysin, a brain-derived peptidergic drug known to support neuronal survival, improved brain function in nine RS girls. This drug did not increase frequency or severity of seizures; in fact, it appeared to eliminate seizures in one case (Gorbachevskaya, Bashina, Gratchev, & Iznak, 2001). Some research suggests the efficacy of melatonin in reducing latency of sleep onset, with data also suggesting a mild trend towards increasing overall sleep time (McArthur & Budden, 1998).…”

Section: Treatmentsmentioning

confidence: 92%

Recognizing and treating Rett syndrome in schools

Wanzek

Jenson

Houlihan

2011

School Psychology International

View full text Add to dashboard Cite

A review of the literature on Rett syndrome (RS) for school-based professionals is presented from a behavioral perspective. A description of RS is provided, including distinctive physical, behavioral, and emotional features, diagnostic criteria for classic and formes frustes forms of RS, and stages of the disorder. The similarities and differences between RS and autism are reviewed. Controversies regarding the classification of RS are presented, including whether RS should be classified as a neurological or psychiatric condition and whether RS should remain classified as a pervasive developmental disorder. Last, a variety of options for the treatment of RS are discussed.

show abstract

“…croglial activation/neuroinflammation [12][13][14][15]. Additionally, it has been demonstrated to exhibit neurotrophic activity, promote neuronal sprouting, improve cellular survival and stimulate neurogenesis [16][17][18]. However, our literature review showed that there is not any study to investigate the effect of Cerebrolysin in the attenuation of Morphine-induced tolerance and dependence.…”

Section: Conclusion In Conclusion It Was Found That Pretreatment Withmentioning

confidence: 94%

Attenuation of Morphine-Induced Tolerance and Dependence by Pretreatment with Cerebrolysin in Male rats

Ghavimi¹,

Darvishi²,

Ghanbarzadeh

2017

Drug Res (Stuttg)

View full text Add to dashboard Cite

show abstract

Cerebrolysin therapy in Rett syndrome: clinical and EEG mapping study

Cited by 26 publications

References 9 publications

Neurobiologically-based treatments in Rett syndrome: opportunities and challenges

Neurobiologically-based treatments in Rett syndrome: opportunities and challenges

Recognizing and treating Rett syndrome in schools

Attenuation of Morphine-Induced Tolerance and Dependence by Pretreatment with Cerebrolysin in Male rats

Contact Info

Product

Resources

About